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cSdringola et al. (1) in this issue of iJACC address an
issue of considerable importance, both for clinical
and for research applications concerning positron
emission tomography (PET) measurements of ab-
solute myocardial blood flow (MBF). In brief, they
attempted what at first blush seems a simple and
obvious task; namely to define “normal” values of
MBF (82Rb method) at rest and with pharmaco-
logical stress (dipyridamole) and coronary flow re-
serve (CFR) ratio (MBFdip/MBFrest). They also
See page 402
sought to determine the reproducibility of these
measurements after a 1-week hiatus between the
first and second studies and to identify what they
term “unexpected” factors that may influence these
measurements and their reproducibility.
The authors recruited 125 apparently healthy,
asymptomatic volunteers between the ages of 20
and 40 years old for the study. Results are reported
for the group as a whole as well as for 2 subgroups,
apparently retrospectively defined as “true normals”
and “not normals” (see Figs. 3 and 4 and Tables 1
and 2 in Sdringola et al. [1]). True normals were
characterized by an absence of all of the following
(Table 1 of Sdringola et al. [1]): coronary calcium
on computed tomography, detectable nicotine or
metabolite, detectable caffeine (1.0 mg/ml), dys-
lipidemia, family history of early coronary artery
disease (CAD), visual PET perfusion defect, elec-
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Gewirtz has received a research grant from FluoroPharma, Inc.rocardiographic evidence of left ventricular hyper-
rophy, or history of hypertension. The subgroup
lassified as “not normal” had 1 or more of the
bove. The authors observed that rest MBF (0.70
.15 ml/min/g, mean  SD) did not differ between
he subgroups. However, MBF with dipyridamole
nd CFR were modestly but statistically greater in
true normals” versus “not normals” (respectively,
.89  0.50 vs. 2.63  0.61; p  0.005, and 4.17
0.80 vs. 3.91  0.86; p  0.05). Reproducibility
oefficient (Table 3 in Sdringola et al. [1]) was
dentical for rest MBF (35%) in the 2 subgroups
nd “improved,” though apparently not signifi-
antly, in “true normals” versus “not normals” for
ipyridamole MBF (34% vs. 41%, respectively) and
FR (38% vs. 51%, respectively). The authors
onclude “unexpected” factors noted in the previous
ext are present in 50% of apparently healthy young
olunteers (“not normals”) and have a small but
tatistically significant impact, primarily on dipyri-
amole MBF and CFR as well as reproducibility of
hese parameters. Accordingly, they suggest a sys-
ematic effort should be made to identify individuals
n whom 1 or more of these factors are present and
o exclude them from any dataset of healthy con-
rols (optimal age, 20 to 40 years, mixed sexes).
Although the goal of the paper is laudable and
he data presented useful, there are several issues
hat are worth considering further. First is the broad
ssue of how to define “normal,” healthy controls. In
he present paper, individuals from 20 to 40 years of
ge of either sex were recruited. Following screen-
ng, as noted previously, roughly 50% were excluded
rom the final dataset of true normals. The reasons
or exclusion in the main, however, should not be
onsidered unexpected. Indeed, the very purpose of
creening urine for evidence of nicotine or caffeine
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414intake, obtaining blood for lipid profile for evidence
of dyslipidemia, and querying for a family history of
premature CAD all reflect the well-known fact that
such potential disqualifiers may be present in an
apparently healthy population of younger individu-
als and so finding same in some of them comes as
no surprise and certainly is not unexpected.
Beyond that, there is the issue of whom to
include in a group of healthy controls. The authors
made certain decisions, especially regarding age,
sex, and lipid profile. Although 20 to 40 years of
age and either sex may be appropriate for certain
experimental designs, it obviously may not be for
others. It is noteworthy in this regard the authors
observed that women had higher rest and
dipyridamole-stimulated MBF than males; an ob-
servation (i.e., higher rest MBF in women) reported
by others (2). Further, use of dipyridamole at the
dose employed in the present study is problematic,
as the authors themselves recognize, since it may
not induce maximal myocardial hyperemia and in
general is less consistent and less potent in the
hyperemic response it produces in comparison with
that of adenosine (2,3), which is readily available
and easily used. Moreover, since almost one-third
of “not normals” (Table 1 in Sdringola et al. [1])
had evidence of caffeine ingestion, it is likely that
much of the variation and lesser response to dipyr-
idamole in this group compared with “true normals”
(Table 3 in Sdringola et al. [1]) reflects the well-
known (and expected) antagonistic effect of meth-
ylxanthines on dipyridamole-induced myocardial
hyperemia.
Age, too, is known to influence rest and maximal
MBF in apparently healthy individuals with low
likelihood for CAD (2,4), and so both age and sex
need to be taken into account when constructing a
“normal” database for comparison to patients either
having diagnostic quantitative PETMBF studies or
those enrolled in clinical trials with quantitative
PET MBF end points. It is possible race, as in the
therapy of hypertension (5,6), also may play a role
in terms of determining normal values for quanti-
tative PETMBF studies. Finally, in this regard, the
authors allude briefly to the fact that differences
both in tracer and kinetic model employed to
measure MBF may interact in ways that impact
the absolute “normal” values both for rest and
stress MBF. Inspection of Table 4 of their paper
(1) indicates a range of “normal” rest MBF from
0.61  0.09 (7) (13N-ammonia) to 1.24  0.19
8) (15 O-water) and stress MBF from 1.86  0.27
(7) to 5.05  0.90 (8). A recent comparison of 82Rb with 13N-ammonia and the same tracer kinetic
model indicated 82 Rb tended to overestimate rest
MBF and underestimate stress (dipyridamole)
MBF in comparison with 13N-ammonia (9). What
all this means is that each laboratory will have to
develop its own normal database using consistent
technical methodology and be prepared to vary the
composition of its subjects based on specifics of the
study design and the hypothesis being tested. One
size will not fit all.
There are several physiological points that also
should be raised, and bear directly on the use of
quantitative PET MBF measurements, both for
clinical and research purposes. First, as the authors
no doubt are aware, the notion of “normal” resting
MBF itself is problematic over and above technical
and epidemiological (e.g., age and sex) consider-
ations. Efforts to correct rest MBF by indexing it to
rate pressure product are crude and generally show
only modest correlation between the two (2). The
reasons for this are likely numerous, but two that
stand out are: 1) correction for rate pressure product
ignores, because it cannot be easily measured, myo-
cardial contractility, a major determinant of MVO2
and hence rest MBF in the normal coronary circu-
lation (the authors allude to this in their discussion
of lower resting MBF on the second visit in their
“true normals” (Table 3 in Sdringola et al. [1]); and
2) heritable variation that undoubtedly plays a
major role and that, in part, may reflect differences
in efficiency of mitochondrial oxidative metabolism
(10,11).
Further, the use of CFR to characterize the
maximal dilator capacity of the coronary circulation
should be discouraged for a variety of reasons. The
authors’ own data indicate it is less reproducible
than MBF with stress (Table 3 in Sdringola et al.
[1]). Since it is a ratio, it has the potential to be
quite misleading, especially if rest MBF is low. A
patient with rest MBF of 0.50 ml/min/g could
double or even triple that flow in response to a
potent coronary vasodilator and only have maximal
MBF of 1.0 to 1.5 ml/min/g, levels that fall in the
normal range of rest MBF in some studies (Table 4
in Sdringola et al. [1]) and almost certainly are
insufficient to deliver required levels of oxygen to
myocardium under conditions of maximal exercise
stress (12). Yet CFR of 2 to 3 is commonly
considered “normal” (13) and would fall within 2
SD of the mean reported in the current study
(4.03  0.85) (Table 4 in Sdringola et al. [1]).
Moreover, it has been shown that a single mea-
surement of adenosine-stimulated maximal myo-
C
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415cardial blood flow provides excellent discrimina-
tion between coronary vessels with 70%
stenosis and those with lesser or no stenosis (14).
Accordingly, there is little to be gained by mea-
suring rest MBF for purposes of computing CFR
if the objective of the endeavor is to diagnose
CAD or assess the response to an intervention
designed to increase maximal MBF.
In summary, therefore, the paper by Sdringola et
al. (1) demonstrates the need for meticulous atten-





with mitochondriadatabase for quantitative PET measurements of
MBF and in the requirement for thoughtful con-
sideration of who those subjects should be. As with
most well-done papers, it also raises a number of
issues, noted in the previous text, worthy of addi-
tional consideration and future research.
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